Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
In the often-overlooked world of micro-cap equities, few stories stand out for their clarity of vision and breadth of execution like the unfolding transformation of HST Global Inc. (OTC: HSTC). After years of stagnation, the Nevada-based company—now operating out of Virginia Beach, VA is undergoing a bold and unconventional reboot under the leadership of Mike Field and Jason Murphy.
The new management team, which took control in a sweeping April 2024 reorganization, has turned what was essentially a dormant shell into an operational holding company with assets in biotech, consumer services, transportation, and encrypted communications. HSTC’s strategy: balance speculative long-term plays with near-term revenue-generating ventures, all while maintaining the transparency of a public entity with a major caveat from its President who referred to the venture as "Extremely Speculative" in nature.
A cornerstone of this transformation is the October 2024 acquisition of Amnion LLC, a Virginia-based tissue technology firm founded by Mike Fortkort. Specializing in placenta-derived grafts used in wound care and surgical recovery, Amnion brings FDA-compliant infrastructure and IP into the fold. The company’s products, featured at www.amnion.net, harness amniotic and chorionic membranes to promote healing in chronic and acute wounds.
Amnion is currently building out a GMP-compliant lab in Sterling, Virginia, with operations expected to begin by year-end. The acquisition is HSTC’s first major step into high-regulation, high-margin healthcare markets, and positions it as a rare micro-cap play with a foot in the biologics sector.
Meanwhile, HSTC is developing a portfolio of scalable, tech-enabled home and personal services brands through its August 2024 acquisition of IP. The transaction brought in multiple trademarked domains including MowTrimBlow.com, DemiFare.com, and JetSeg.com—each designed to capture hyperlocal market share in fragmented service verticals like landscaping, mosquito control, and short-haul transport.
Key to the initiative is consultation with long term investors Sagie Doron and Tim Skeen. Their goal is to continue to grow and systematize the delivery of services under a unified branding and scheduling platform, enabling future franchise or licensing expansion.
While HST’s efforts in biologics and home services are grabbing headlines, two recent moves point to further diversification:
For a company that just over a year ago had fewer than $2,000 in cash and no revenues, the HST Global story is gaining credibility among seasoned micro-cap observers. With a cleaned-up balance sheet, over ten million in assets, insider ownership exceeding 80%, and multi-sector exposure, Field and Murphy are attempting what few micro-caps can pull off: a credible, diversified operating company with upside and transparency.
Whether HSTC can scale these early moves into sustainable growth remains to be seen. But in a sector often dominated by hype and dilution, the company’s grounded execution and asset-first strategy are drawing notice—and could mark one of the more significant reinventions in the OTC landscape.